ContraFect

Exebacase

Exebacase

OVERVIEW

To view our CMO present an overview of the exebacase program at the Duke-Margolis Center for Health Policy Forum on Emerging Non-Traditional Antibiotics, please click on the link below

Exebacase (CF-301) is a lysin with potent activity against Staphylococcus aureus ("Staph aureus"). Exebacase has the potential to be the first-in-class of a new treatment for patients with Staph aureus bacteremia. The addition of exebacase to either vancomycin or daptomycin increased survival significantly in animal models of disease when compared to treatment with SOC antibiotics or exebacase alone. Exebacase targets a highly conserved region of the cell wall that is vital to bacteria, thus making resistance less likely to develop. When used in combination with SOC antibiotics, the result is a novel treatment modality that has the potential to combat the high unmet clinical need of Staph aureus infections.

Exebacase is the first and only lysin to enter human clinical trials in the US and recently completed a Phase 2 superiority study evaluating the safety efficacy and tolerability of exebacase in patients with Staph aureus bacteremia, including endocarditis. In particular, the improvement in patient response rates of the pre-specified MRSA population was remarkable across the whole MRSA population (42.8% improvement; p=.010) as well as MRSA subgroups – by SOC antibiotic, source of infection or complicated bacteremia – establishes the basis on which exebacase will be studied in Phase 3.